2011

More and more pharmaceutical company employees are using Twitter. Pharmaguy is looking at pharma employees who have personal Twitter accounts, how they use these accounts, who follows them and whom they follow, and how influential they are. This article is an introduction to the first round of members of this group.

Pharmaceutical marketers have jumped on the mobile application bandwagon as more and more companies roll out health-related applications for smartphones and touchpads such as Apple's iPhone and iPad. But will the FDA regulate certain smartphone apps as medical devices? This article discusses the regulatory and other issues associated with pharma developed or sponsored health apps.

The pharmaceutical industry has been very generous in making payments to physicians. Last year (2010), for example, a mere dozen pharmaceutical companies paid $760 million to physicians and other health care providers for consulting, speaking, research and expenses. On average, how much do you think that comes to for every physician in the U.S.?

Welcome to Volume 10, Issue #10 (8 JUNE 2011) of Pharma Marketing News.

How many patients are needed these days to make a drug a billion dollar blockbuster? Less than you think. What are the implications for pharmaceutical marketing?

According to a recent CDC Data Brief, antidepressants were the third most common prescription drug taken by Americans of all ages in 2005–2008 and the most frequently used by persons aged 18–44 years. From 1988–1994 through 2005–2008, the rate of antidepressant use in the United States among all ages increased nearly 400%. Perhaps not so coincidentally, antidepressants are among the TOP advertised Rx category in 2010, according to the recent AdAge analysis.

In a recent blog post, PhRMA said 'Without Promotion Research will be Useless.' To support its case, PhRMA cited 'an interesting opinion editorial' in the latest edition of the Annals of Emergency Medicine -- the medical journal of the American College of Emergency Physicians (ACEP). In the op-ed, entitled 'Limiting Gifts, Harming Patients,' Emory University economist Paul Rubin, Ph.D. expressed concern that ACEP policy regarding Gifts to Emergency Physicians from Industry 'could have the unfortunate effect of limiting the exchange of critical information between medicine makers and physicians about the benefits and risks of new medicines, how to use them properly and how best to diagnose the right candidates for particular treatments.'

Welcome to Volume 10, Issue #12 (20 JULY 2011) of Pharma Marketing News.

An anonymous poster to CafePharma described what the

Welcome to Volume 10, Issue #5 (10 MARCH 2011) of Pharma Marketing News.